Genetic polymorphisms of RAD51 and XRCC3 and acute myeloid leukemia risk: a meta-analysis

Abstract

Studies on gene polymorphisms of RAD51 and X-ray repair cross-complementing group 3 (XRCC3) and acute myeloid leukemia risk (AML) are conflicting and there is no recent meta-analysis. Therefore, the purpose of this study was to evaluate the effect of RAD51 G135C and XRCC3 Thr241Met genotypes on AML susceptibility. We conducted a systematic search of three databases including PubMed and EMBASE for the period up to 20 February 2013 and identified 43 relevant studies. Six eligible studies were eventually selected for RAD51 (1764 cases and 3469 controls) and six studies for XRCC3 (1352 cases and 2582 controls). Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of AML associated with RAD51 and XRCC3 were appropriately calculated based on fixed- or random-effects models. The quality of studies was evaluated using the Newcastle-Ottawa Scale (NOS). Subgroup analyses were performed among Asian, Caucasian and other populations. The pooled results showed that the leukemia risk was not significantly associated with RAD51: the same results were obtained among any subgroup analysis. No significant association was demonstrated for AML risk with XRCC3 in the total population, but elevated associations were observed in Caucasians for the homozygote and recessive comparison (Met/Met vs. Thr/Thr, OR = 1.67, 95% CI = 1.09–2.57, p = 0.019; recessive model, OR = 1.78, 95% CI = 1.19–2.65, p = 0.005). This meta-analysis provides evidence that the RAD51 and XRCC3 polymorphisms are not associated with an increased risk of AML in the total population.

Keywords::

• RAD51
• XRCC3
• polymorphisms
• acute myeloid leukemia
• meta-analysis

Acknowledgement

We are thankful to all participants of our study.

Potential conflict of interest:

Disclosure forms provided by the authors are available with the full text of this article at www.informahealthcare.com/lal.